| INTRODUCTION
Of the approximately 70 million persons chronically infected with hepatitis C virus (HCV) globally, approximately 90% reside in lowand-middle-income countries (LMICs).
1 With the advent of directacting antivirals (DAA), HCV infection is curable with 12 weeks of all-oral, nontoxic agents. [2] [3] [4] [5] [6] With these remarkable developments, the World Health Organization released the first HCV global elimination targets for 2030. 7 The goal is to achieve 90% reduction in new cases and 65% reduction in HCV-associated mortality. Achieving these ambitious goals will require massive treatment scale-up in most countries where only about 5% of persons with chronic HCV have been diagnosed and fewer than 2% treated. Elimination programmes in some settings 8, 9 have been facilitated by licensing and preferential pricing agreements and production of generic versions of new DAA, which have brought costs down to <500 USD/treatment course.
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However, as elimination programmes shift towards HCV treatment delivery, they must take into consideration factors other than provision of free medications. First, while costs associated with medications have decreased substantially in some places, monitoring costs remain unchanged (for example, in India it costs ~80 USD for HCV RNA and ~90 USD for HCV genotype testing). Moreover, infrastructure for viral load and genotyping is not available in many LMICs. Second, elimination strategies will need to target all persons infected including drugusing populations who bear a disproportionate HCV burden and may have adherence challenges.
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Directly observed therapy (DOT), the standard of care for TB, 12 has been demonstrated to improve treatment completion and response rates for TB, 13,14 HIV 15 and HCV. [16] [17] [18] [19] [20] Using modified DOT, HCV treatment has been successfully delivered in opioid treatment programmes [16] [17] [18] and prison settings 19 consistently demonstrating improvements in adherence and cure rates. [16] [17] [18] [19] [20] These trials, however, were conducted in the pre-DAA era when regimens were more complicated (twice daily dosing and weekly injections). Further, none were conducted in an LMIC. Key barriers to DOT consistently identified are transportation and patient-level inconvenience, which can lead to missed doses and dropouts, 14, 21 barriers which may be amplified in LMICs, where many patients are daily wage earners.
In India, it is estimated that there are approximately 6.3 million viremic HCV-infected persons. 1 India is also home to the largest number of opioid users globally (~3 million) with HCV prevalence of ~37% among people who inject drugs (PWID). 22 Generic sofosbuvir was licensed in India in 2015, and 11 generic forms are available at a maximum retail price of 300 USD/28 tablets. 10 However, delivery challenges remain. The goal of this trial was to leverage a rich history of DOT in India (cornerstone of the Indian National Tuberculosis Programme) 23 and the dearth of molecular testing to assess the feasibility of field-based DOT with minimal monitoring to deliver HCV therapy to people who use drugs in Chennai, India. We directly compared the safety and efficacy of the only two pan-genotypic HCV regimens available in India in 2015. 24 
| MATERIALS AND METHODS

| Study setting and population
| Study endpoints and statistical analysis
The primary endpoint was treatment completion defined as com- , and (iii) change in insulin resistance measured by HOMA-IR. Changes in HOMA-IR were based on fasting laboratory assessments at baseline and SVR12 visit. We also captured information on quality of life using the EQ-5D which includes a visual analogue scale (VAS) of self-rated health quality from 0 (worst health state) to 100 (best health state). 
| Ethical clearances
This study was approved by the Johns Hopkins Medicine and YRGCARE institutional review boards, and all participants provided written informed consent.
| RESULTS
We screened 98 participants, of whom, 61 were eligible and 50 enrolled ( Figure 1) ; Common reasons for exclusion were no active HCV infection (n=24), HIV-positive status with CD4<350 or not on a tenofovir-containing regimen (n=4) and creatinine clearance<60 mL/ min (n=4). The median age was 46 (interquartile range, 42-49). All were male and the majority (54%) had less than high school education, with a median monthly income of 90 USD/month (Table 1) ; 24 (48%) were daily wage earners. Two participants were co-infected with HIV; one was on ART. All participants self-reported that they had injected drugs in the past-one participant self-reported that he was actively injecting at entry into the trial. Eighteen per cent reported active noninjection drug use, and 38% had an AUDIT score consistent with dependence. Based on elastography (Fibroscan), the majority (58%) had no/mild liver stiffness (<8.5 kPa), 22% had moderate stiffness (8.5-12.3 kPa) and 20% severe stiffness/cirrhosis (>12.3 kPa).
The median AST, ALT and FIB-4 measurements were 49 U/L, 42 U/L and 2.2, respectively. The median HCV RNA level was 6.4 log 10 IU/mL.
Post-treatment testing revealed that the majority of participants were infected with genotype 3 (n=42, 84%) followed by genotype 1 (n=7, 14%).
| Outcomes
| Primary outcome
Among the 50 participants, six discontinued treatment (three per arm)
for a treatment completion rate of 88% in each arm (Table 2) . Of the six participants who discontinued treatment, three discontinued in the first week, and one each in weeks 4, 5 and 6 (Table 3) . Despite these discontinuations, we obtained a specimen to examine SVR12 in one participant who received 23 days of SOF+PR before stopping.
Reasons for discontinuation are in Figure 1 . E1 regions were sequenced on the 12-week post-treatment specimens, and the genotype was identical to the baseline in all specimens; however, more detailed phylogenetic analyses were not conducted to distinguish relapse and re-infection. There were no treatment failures on SOF+PR, but of those that did not complete SOF+PR, two had genotype 1a and one had genotype 3a infection.
| Secondary outcomes
For the one participant treated with SOF+PR from which we obtained a postdiscontinuation sample, HCV RNA was 6.5 IU/mL. No serious adverse events occurred; the frequency of adverse events was comparable across arms (Table S1 ). The median change in HOMA-IR in the SOF+PR arm and SOF+R arms were 1.2 and 0.2, respectively (P=.30).
| Exploratory outcomes
Of the 44 who completed treatment, the median number of missed doses of oral medication was two in SOF+PR (range: 0-18) and six in SOF+R (range: 0-39). No peginterferon injections were missed for those who completed treatment.
| Factors associated with treatment completion and SVR12
We further assessed whether treatment completion and SVR12 
| DISCUSSION
This study is among the first to evaluate directly observed delivery of DAA-based therapy in populations with a history of substance use in an LMIC setting. Our findings provide some insight into the realization of the global HCV elimination goals. First, these data support that substance using populations in a LMIC setting can be cured of HCV using a field-based DOT approach. Second, the data support that therapeutic monitoring before and during can be dramatically simplified including the removal of genotype determination. Third, HCV therapy can be delivered in LMICs with minimal infrastructure and staffing.
Treatment delivery and monitoring can potentially be even further simplified with newer ribavirin-free pan-genotypic regimens and advances in diagnostics (e.g Cepheid GeneXpert HCV RNA testing). Measured using the EQ 5D-3L instrument.
T A B L E 1 (Continued) treatment and (ii) the long half-life of peginterferon can be forgiving of occasional missed doses.
Treatment completion rates were high and comparable in both groups in this trial, but SVR12 among those who completed treatment was significantly higher in those who received SOF+PR (100%) compared to those that received SOF+R (68% we found low SVR12 among those with genotype 1 infection; only one of four genotype 1 patients who completed treatment with SOF+R achieved SVR12. However, the three patients who failed had characteristics previously associated with poor treatment response. One was actively using drugs and missed 32 doses and two had high pretreatment viral loads and cirrhosis (liver stiffness>30 kPa). These lower response rates are consistent with the NIH SPARE trial, which included genotype 1 infected patients with unfavourable treatment predictors, and observed efficacy of 24 weeks of SOF+R to be 68% in those receiving weight-based ribavirin and 48% in those receiving low-dose ribavirin.
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Collectively, these data speak to the possibility of achieving cure in substance using populations using DOT, but also highlight challenges. On the one hand, the field-based DOT strategy that we used In this study, as we used pan-genotypic regimens with demonstrated efficacy and no stopping rules, we opted for a minimal number of monitoring tests. No genotyping was performed prior to treatment initiation and neither on-treatment nor end-of-treatment HCV RNA testing was performed. The only safety monitoring included a monthly complete blood count. Despite this, our treatment outcomes were comparable to other reports and, even using agents historically considered to be "highly toxic," no participant experienced an SAE. It can be argued that some on-treatment monitoring, in particular, the 4-week HCV RNA level, may be an important adherence intervention in and of itself. In our study, the absence of this measurement likely had little impact because we maintained daily contact with participants. 
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; all were also trained to provide counselling. As LMICs begin to implement elimination programmes, scaling up these types of community clinics to provide HCV treatment may prove critical. Global experience with delivering HIV treatment in similar settings has demonstrated that accessibility is a key facilitator. 40 For HCV, infrastructure required is even more minimal than what is needed for HIV and would include linkage to laboratory that can perform simple tests (e.g FIB-4), a rapid HCV RNA measure (e.g Cepheid GeneXpert), a clinician (nurse or doctor) and support staff (e.g outreach workers).
We were concerned about the acceptability of peginterferon particularly because prior observational studies in India have suggested patient preference for SOF+R for 24 weeks over SOF+PR for 12 weeks due to inaccessibility of facilities providing peginterferon, financial constraints (peginterferon is expensive) and fear of side effects.
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However, in this trial, no participants refused participation because of the potential of being randomized to receive peginterferon. In fact, some participants were disappointed not to have been randomized to receive "injections". In India, particularly in lower-income groups, there is widespread belief that injections are more potent than pills. The annual per capita number of injections ranges from 3 to 6, durations (e.g 4 or 6 weeks) in substance using populations (both alcohol and drug use) and others with potentially poor adherence.
Several limitations must be acknowledged. The sample size is small and precluded additional subgroup comparisons. Even those that were conducted should be considered exploratory. We conducted this trial prior to the availability of daclatasvir and velpatasvir in India-these combinations (SOF+DAC or SOF+VEL) are superior to SOF+R with respect to SVR and it possible that these regimens could also be more forgiving of missed doses. However, the potential to shorten duration dramatically 
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In conclusion, these data demonstrate the feasibility of curing HCV in persons with a history of substance use in an LMIC setting with minimal use of molecular tests and limited infrastructure using a fieldbased DOT approach. Simplification of regimens will further facilitate delivery of these medications in such settings. Important challenges remain particularly related to ongoing substance use and nonadherence;
there may still be a role for peginterferon in these sub-populations.
